Amarin Corporation

Amarin Corporation Financial Leverage

The Financial Leverage (Equity Multiplier) of Amarin Corporation (AMRN) as of Nov 19, 2026 is 1.46. In the previous year, Financial Leverage (Equity Multiplier) was 1.41 — a change of 3.60% (higher).

Financial Leverage

1.46

YoY

3.60%

Last updated:

Financial Leverage (Equity Multiplier) of Amarin Corporation is 2025 1.46 . Financial Leverage (Equity Multiplier) of Amarin Corporation was 2024 1.41 . It decreases by 3.60% higher compared to the previous year.

The Amarin Corporation Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
2.53 USD
Jan 1, 2019
1.45 USD
Jan 1, 2020
1.54 USD
Jan 1, 2021
1.60 USD
Jan 1, 2022
1.49 USD
Jan 1, 2023
1.51 USD
Jan 1, 2024
1.41 USD
Jan 1, 2025
1.46 USD
The Amarin Corporation Financial Leverage history
YEARFinancial LeverageYoY
1.46+3.60%
1.41-6.42%
1.51+1.20%
1.49-7.03%
1.60+4.00%
1.54+6.14%
1.45-42.72%
2.53-202.01%
-2.48-86.54%
-18.44+1,273.12%
-1.34-30.59%
-1.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Financial Leverage (Equity Multiplier) of Amarin Corporation is 1.46 in 2025.

Financial Leverage (Equity Multiplier) of Amarin Corporation changed from 1.41 to 1.46, representing a 3.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Amarin Corporation

All Key Metrics — Amarin Corporation